We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About AgomAb Therapeutics Stock

Invest in or calculate the value of your shares in AgomAb Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

AgomAb Therapeutics Stock (AGTH)

AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.

About AgomAb Therapeutics Stock

Founded

2017

Industries

Software, Artificial Intelligence, Data and Analytics

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

AgomAb Therapeutics Press Mentions

Stay in the know about the latest news on AgomAb Therapeutics

AgomAb Therapeutics Management

Leadership team at AgomAb Therapeutics

Co-founder

Virginia Morello

Chief Executive Officer

Tim Knotnerus

Locked Features

Join now and verify your accreditation status to gain access to:

  • AgomAb Therapeutics current valuation
  • AgomAb Therapeutics stock price
  • Available deals in AgomAb Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in AgomAb Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like AgomAb Therapeutics through EquityZen funds. These investments are made available by existing AgomAb Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell AgomAb Therapeutics stock?

Shareholders can sell their AgomAb Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."